drugset / Trial / NCT07739914
Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)
RandomizedParallel-groupOpen-labelTreatment
Summary
The overall aim of this study is nephroprotection based on a calcineurin inhibitor (CNI)-free therapy beyond year one after orthotopic liver transplantation (OLT) in highly pre-selected patients with low rejection risk.
Timeline
- Start
- 2026-08-19
- Primary completion
- 2029-06-30
- Completion
- 2031-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | — | — |
| Subject | Everolimus | Small molecule | — | — |
| Comparator | Tacrolimus | Small molecule | — | — |